OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
Collin M. Blakely, Anatoly Urisman, Matthew A. Gubens, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 26, pp. 3105-3114
Open Access | Times Cited: 17
Collin M. Blakely, Anatoly Urisman, Matthew A. Gubens, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 26, pp. 3105-3114
Open Access | Times Cited: 17
Showing 17 citing articles:
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
Claudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
Cancer Treatment Reviews (2024) Vol. 131, pp. 102845-102845
Closed Access | Times Cited: 4
Claudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
Cancer Treatment Reviews (2024) Vol. 131, pp. 102845-102845
Closed Access | Times Cited: 4
Advances in adjuvant therapy for operable N2 non-small cell lung cancer: a narrative review
Lei Liu, Yan‐Ping Mao, Leilei Guo, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Lei Liu, Yan‐Ping Mao, Leilei Guo, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Salvage Surgery for Epidermal Growth Factor Receptor-Mutant Lung Cancer With Osimertinib Resistance: A Case Report
Shinya Otsuka, Yutaro Nagano, Makoto Shioya, et al.
Cureus (2025)
Open Access
Shinya Otsuka, Yutaro Nagano, Makoto Shioya, et al.
Cureus (2025)
Open Access
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives
Lucrezia Barcellini, Simone Nardin, G. Sacco, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 652-652
Open Access
Lucrezia Barcellini, Simone Nardin, G. Sacco, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 652-652
Open Access
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
RBM10 deficiency promotes brain metastasis by modulating sphingolipid metabolism in a BBB model of EGFR mutant lung adenocarcinoma
Gang Xu, Bo An, Ruqiong Wang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Gang Xu, Bo An, Ruqiong Wang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Pathological complete response and long-term survival by pembrolizumab based immunochemotherapy in epidermal growth factor receptor mutated non-small cell lung cancer post-tyrosine kinase inhibitor failure: a case report and tumor microenvironment analysis
Sangtian Liu, Wenhua Liang, Stuart H. Q. Quan, et al.
Translational Lung Cancer Research (2025) Vol. 14, Iss. 3, pp. 1032-1041
Open Access
Sangtian Liu, Wenhua Liang, Stuart H. Q. Quan, et al.
Translational Lung Cancer Research (2025) Vol. 14, Iss. 3, pp. 1032-1041
Open Access
Real-World Performance of the EasyPGX® Ready Epidermal Growth Factor Receptor Assay for Genomic Testing of Non-Small Cell Lung Cancer Samples
Michael B. Schmid, Izadora Demmer, Sandra Floriani, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 814-814
Open Access
Michael B. Schmid, Izadora Demmer, Sandra Floriani, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 814-814
Open Access
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
Dongliang Bian, Shuyu Ji, Yue Liu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Dongliang Bian, Shuyu Ji, Yue Liu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Alternative Splicing in Lung Adenocarcinoma: From Bench to Bedside
Wenjie Luo, Mingjing Xu, Nathalie Wong, et al.
Cancers (2025) Vol. 17, Iss. 8, pp. 1329-1329
Open Access
Wenjie Luo, Mingjing Xu, Nathalie Wong, et al.
Cancers (2025) Vol. 17, Iss. 8, pp. 1329-1329
Open Access
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, et al.
Current Oncology (2024) Vol. 31, Iss. 9, pp. 5121-5139
Open Access | Times Cited: 3
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, et al.
Current Oncology (2024) Vol. 31, Iss. 9, pp. 5121-5139
Open Access | Times Cited: 3
Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report
Rongzhen Li, Xiaoyan Liu, Yan Xu, et al.
Thoracic Cancer (2024)
Open Access | Times Cited: 2
Rongzhen Li, Xiaoyan Liu, Yan Xu, et al.
Thoracic Cancer (2024)
Open Access | Times Cited: 2
Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials
Kaiqi Chen, Xin Wei Wang, Rui Yue, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Kaiqi Chen, Xin Wei Wang, Rui Yue, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Inoperable Stage III EGFR Mutant Non-Small Cell Lung Cancer: time for drug first, local later?
Alexius John, Fiona McDonald, S. Popat
Annals of Oncology (2024)
Closed Access
Alexius John, Fiona McDonald, S. Popat
Annals of Oncology (2024)
Closed Access
Rebuilding TME may open new doors for improving the prognosis of EGFR mutation patients
Rui Han, Conghua Lu, Yong He
Cancer Letters (2024), pp. 217323-217323
Closed Access
Rui Han, Conghua Lu, Yong He
Cancer Letters (2024), pp. 217323-217323
Closed Access
Global trends and research hotspots in perioperative management of lung cancer: a bibliometric analysis from 2004 to 2024
Qinling Jiang, Zhiqiang Wei, Pingping Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Qinling Jiang, Zhiqiang Wei, Pingping Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
